Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation.
Ting-Hao Tu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · In vivo (Athens, Greece) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits, this is the first case report to highlight severe MTX-induced myelosuppression in an RA patient and to demonstrate the potential of molecular hydrogen therapy in modulating immune markers. These findings add human evidence supporting molecular hydrogen's therapeutic potential for rheumatoid arthritis.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits. This is the first case report to highlight severe MTX-induced myelosuppression in an RA patient and to demonstrate the potential of molecular hydrogen therapy in modulating immune markers.
What the Researchers Studied
The researchers studied Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits.
What Effects Did Molecular Hydrogen Have?
Molecular hydrogen, recognized for its anti-inflammatory and antioxidant properties, has demonstrated potential in mitigating oxidative stress and modulating immune responses in RA. This study aimed to evaluate the efficacy of molecular hydrogen therapy in alleviating MTX-induced myelosuppression while preserving its immunoregulatory effects in a patient with RA. Outpatient medications were discontinued, and molecular hydrogen therapy was initiated. This is the first case report to highlight severe MTX-induced myelosuppression in an RA patient and to demonstrate the potential of molecular hydrogen therapy in modulating immune markers.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for rheumatoid arthritis and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.